Ladanifer
- The US FDA has granted Fast Track designation to KT-621, a potential first-in-class oral STAT6 degrader for atopic dermatitis, from Kymera Therapeutics (KYMR).
- The development follows the release of positive phase 1 data on the candidate on Dec. 8 that sent shares surging.
- KT-621 is currently in phase 2.Â